Published in Lancet Infect Dis on July 22, 2014
Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex With Men | NCT02864550
PC4PrEP: Integrating PrEP Into Primary Care (PC4PrEP) | NCT03617874
Testing of the Smartphone App to Enhance HIV Prevention Cascade Among Malaysian MSM | NCT05044013
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med (2016) 3.82
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med (2016) 2.86
No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis (2015) 2.40
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA (2016) 2.23
Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. Clin Infect Dis (2015) 2.08
A systematic review of recent smartphone, Internet and Web 2.0 interventions to address the HIV continuum of care. Curr HIV/AIDS Rep (2015) 1.53
Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV AIDS (Auckl) (2015) 1.31
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV (2015) 1.31
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS (2015) 1.30
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis (2016) 1.26
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS (2016) 1.20
State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected MSM in the United States. AIDS (2015) 1.19
Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis (2014) 1.16
Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc (2015) 1.14
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. PLoS Med (2016) 1.10
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc (2017) 1.06
Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep (2015) 1.04
Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc (2016) 1.04
Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS (2016) 1.04
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS (2016) 0.99
Correlates of PrEP Indication in a Multi-Site Cohort of Young HIV-Uninfected Transgender Women. AIDS Behav (2016) 0.98
The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. Curr Opin HIV AIDS (2016) 0.98
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. PLoS One (2016) 0.97
Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr (2015) 0.96
Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS (2015) 0.96
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States. J Infect Dis (2016) 0.96
HIV providers' likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. AIDS Care (2016) 0.95
Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol (2015) 0.95
Tailored combination prevention packages and PrEP for young key populations. J Int AIDS Soc (2015) 0.93
Sources of HIV infection among men having sex with men and implications for prevention. Sci Transl Med (2016) 0.93
Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men. AIDS Behav (2016) 0.92
Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. AIDS Patient Care STDS (2015) 0.91
The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc (2015) 0.91
Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis. Clin Infect Dis (2015) 0.90
Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs (2015) 0.90
The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS (2016) 0.90
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal (2016) 0.90
Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. PLoS One (2015) 0.89
Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2015) 0.89
HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study. J Int AIDS Soc (2015) 0.89
Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project. J Acquir Immune Defic Syndr (2016) 0.89
Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. J Int AIDS Soc (2015) 0.88
Will risk compensation accompany pre-exposure prophylaxis for HIV? Virtual Mentor (2014) 0.88
The current status of the use of oral medication to prevent HIV transmission. Curr Opin HIV AIDS (2015) 0.88
HIV and Sexually Transmitted Infection Incidence and Associated Risk Factors Among High-Risk MSM and Male-to-Female Transgender Women in Lima, Peru. J Acquir Immune Defic Syndr (2015) 0.88
Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative review. HIV AIDS (Auckl) (2015) 0.87
HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. AIDS Res Hum Retroviruses (2015) 0.87
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses (2014) 0.87
Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV. J Int AIDS Soc (2015) 0.87
Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis (2015) 0.87
How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores". Am J Public Health (2015) 0.87
Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study. J Int AIDS Soc (2016) 0.87
Behavioral Interventions to Prevent HIV Transmission and Acquisition for Transgender Women: A Critical Review. J Acquir Immune Defic Syndr (2016) 0.85
Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. Open Forum Infect Dis (2015) 0.85
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr (2017) 0.84
Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S. AIDS Behav (2016) 0.84
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav (2015) 0.83
Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses (2016) 0.83
Pre-exposure prophylaxis in Southern Africa: feasible or not? J Int AIDS Soc (2015) 0.83
Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role. J Acquir Immune Defic Syndr (2015) 0.82
High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One (2014) 0.82
Seasons of Risk: Anticipated Behavior on Vacation and Interest in Episodic Antiretroviral Pre-exposure Prophylaxis (PrEP) Among a Large National Sample of U.S. Men Who have Sex with Men (MSM). AIDS Behav (2016) 0.82
Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2016) 0.82
Defining the HIV Pre-Exposure Prophylaxis Care Continuum. AIDS (2017) 0.81
Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis (2015) 0.81
Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. Curr Treat Options Infect Dis (2015) 0.81
Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS One (2017) 0.81
Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention. J Acquir Immune Defic Syndr (2017) 0.80
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. J Acquir Immune Defic Syndr (2016) 0.79
Ten Years of Screening and Testing for Acute HIV Infection in North Carolina. J Acquir Immune Defic Syndr (2016) 0.79
Differences in Attitudes About HIV Pre-Exposure Prophylaxis Use Among Stimulant Versus Alcohol Using Men Who Have Sex with Men. AIDS Behav (2016) 0.79
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV (2016) 0.78
Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". AIDS Behav (2016) 0.78
Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS (2017) 0.78
Individual HIV Risk versus Population Impact of Risk Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex with Men. PLoS One (2017) 0.78
Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles. AIDS Behav (2016) 0.78
Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States. J Med Internet Res (2016) 0.77
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother (2016) 0.77
Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. AIDS Behav (2016) 0.77
Pharmacology supports on-demand PrEP. Lancet HIV (2016) 0.77
HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia. PLoS One (2016) 0.77
Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. AIDS Behav (2016) 0.77
Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. AIDS Care (2016) 0.77
Demographic Differences in PrEP-Related Stereotypes: Implications for Implementation. AIDS Behav (2015) 0.77
Moving HIV PrEP from research into practice. Lancet Infect Dis (2014) 0.77
Animal and human mucosal tissue models to study HIV biomedical interventions: can we predict success? J Int AIDS Soc (2015) 0.77
Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. Open Forum Infect Dis (2015) 0.77
The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc (2016) 0.76
A novel Online-to-Offline (O2O) model for pre-exposure prophylaxis and HIV testing scale up. J Int AIDS Soc (2017) 0.76
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis (2016) 0.76
Intimacy, condom use, and pre-exposure prophylaxis (PReP) acceptability among men who have sex with men (MSM) in primary partnerships: a comment on Gamarel and Golub. Ann Behav Med (2015) 0.76
Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS (2016) 0.76
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infect Dis Ther (2016) 0.76
The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA. Curr Opin HIV AIDS (2016) 0.75
Modeling HIV vaccine trials of the future. Curr Opin HIV AIDS (2016) 0.75
Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. J Int AIDS Soc (2016) 0.75
HIV pre-exposure prophylaxis for women. J Virus Erad (2016) 0.75
Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity. AIDS (2016) 0.75
Pre-exposure and postexposure prophylaxes and the combination HIV prevention methods (The Combine! Study): protocol for a pragmatic clinical trial at public healthcare clinics in Brazil. BMJ Open (2015) 0.75
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV (2015) 1.31
HIV moments and pre-exposure prophylaxis. Lancet (2016) 1.08
Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). AIDS Behav (2016) 0.81
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV (2016) 0.78
The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. AIDS Behav (2016) 0.75
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV (2017) 0.75
PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply. Lancet HIV (2016) 0.75